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unlikely by ultra deep sequencing of the MLH1 variant in 
DNA isolated from normal mucosa, blood, urine and saliva. 
Although initially being suspect for Lynch syndrome it was 
eventually concluded that a metachronously diagnosed colon 
carcinoma that metastasized to both ovaries was most likely.
Keywords Lynch syndrome · Ovarian cancer · Colon 
cancer
Introduction
In this report we describe a female patient diagnosed with 
bilateral endometrioid carcinoma of the ovaries at the 
age of 44. One year later an adenocarcinoma of the colon 
was detected. The discovery of the colon carcinoma cre-
ated doubt about the primary origin of the ovarian tumors. 
Besides, because the patient met the Amsterdam/Bethesda 
revised criteria, Lynch syndrome (LS) was suggested.
The ovaries can be affected by metastases from several 
primary tumor sites [1]. Most metastases originate from the 
gastrointestinal tract, with the colon as most frequent pri-
mary location. However, primary ovarian tumors are more 
common than ovarian metastases; 85 versus 15% [2]. Since 
subtypes of primary ovarian cancers (especially endometri-
oid and mucinous adenocarcinomas) can show overlapping 
histological and immunohistochemical features with gastro-
intestinal tumor metastases, it can be difficult to discriminate 
these [3, 4]. A combined analysis of clinical and molecular 
features can be helpful in correctly diagnosing these tumors. 
Reanalyis of this case revealed both macroscopic and micro-
scopic evidence for a colonic origin of the ovarian tumors. 
This thought was supported by up-to-date extensive molecu-
lar analyses that showed a clonal relationship between both 
Abstract Patients synchronously or metachronously pre-
senting with ovarian and colon cancer can pose diagnostic 
challenges. A primary colon carcinoma can metastasize to 
one or both ovaries, two independent primary tumors can 
arise or an ovarian carcinoma can metastasize to the colon. 
Clinical and immunohistochemical characterization can aid 
the diagnosis. Recently, we reported that in difficult cases 
finding pathogenic APC variants supports a colonic origin.
In this case report we describe the clinical history of a 
female patient suspected for Lynch syndrome. She was diag-
nosed with a bilateral ovarian cancer at age 44, followed 
by the detection of a colon carcinoma 12.5 months later. 
Lesions of both sites showed a DNA mismatch repair defi-
ciency with immunohistochemical loss of MLH1 and PMS2 
expression without MLH1 promoter hypermethylation. In 
absence of germline MMR gene variants identical somatic 
MLH1 and CTNNB1 gene variants were found, indicating 
a clonal relation. MMR germline mosaicism was made 
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tumors. Lynch syndrome, including DNA mismatch repair 
gene mosaicism, was ruled out.
Materials and methods
Immunohistochemistry
Immunohistochemistry was performed as previously 
described [5]. The antibodies and dilutions that were used 
are as follows: MSH2 (1:25; DAKO Santa Clara, United 
States), MSH6 (1:400; GeneTex Irvine, United States), 
PMS2 (1:80; DAKO Santa Clara, United States) and MLH1 
(1:40; DAKO Santa Clara, United States), CDX2 (1:80; 
DAKO Santa Clara, United States), keratin-7 (1:400; DAKO 
Santa Clara, United States), keratin-20 (1:200; DAKO Santa 
Clara, United States), ER (1:40; DAKO Santa Clara, United 
States), PR (1:400; DAKO Santa Clara, United States) and 
vimentin (1:1000; DAKO Santa Clara, United States).
Methylation specific assay
The promoter region of MLH1 was analyzed by methylation-
specific multiplex ligation-dependent probe amplification 
(MS-MLPA) as previously described [6].
Microsatellite instability (MSI) analysis
Microsatellite analysis was performed using five mononu-
cleotide microsatellite markers as previously described [7].
Germline analysis
Germline analysis of MLH1, PMS2, MHS2 and MSH6 
variant was performed on DNA isolated from lymphocytes 
from a blood sample using standard procedures including 
the analysis for large deletions/duplications by the multiplex 
ligation-dependent probe amplification (MRC Holland, the 
Netherlands).
Somatic and mosaicism analysis
Somatic mutation analysis of MLH1 was performed using 
a laboratory developed multiplex AmpliSeq based NGS 
protocol followed by confirmation of detected mutations by 
Sanger sequencing.
Additional analysis of somatic variations was performed 
on DNA isolated using a fully automated DNA extraction 
procedure. The concentration of DNA was measured using 
a fluorometer (Qubit dsDNA HS, Thermo Fischer Scien-
tific, Waltman MA USA). The amplicon library for targeted 
sequencing was constructed using AmpliSeq Cancer Hot-
spot Panel v2. This panel consists of a single primer pool 
and is designed to detect somatic cancer hotspot patho-
genic variants in 207 amplicons covering 50 cancer related 
genes, including genes as APC, KRAS, TP53, SMAD4 that 
are often altered in colorectal cancer. The whole APC gene 
was analyzed in a separate analysis as in the cancer hotspot 
panel only the mutation cluster region of APC is covered. 
Mosaicism analysis of the identified MLH1 variant was 
performed by using a panel covering MSH2, MSH6, PMS2, 
MLH1, POLD1 and POLE. Libraries were prepared with 
10 ng of genomic DNA, and each sample was uniquely bar-
coded using IonXpress barcodes (Life Technologies). Next-
generation sequencing was carried out according to the Ion 
Proton protocol.
Bioinformatic analysis
The unaligned BAM file generated by the Proton sequencer 
were mapped against the human reference genome 
(GRCh37/hg19) using the TMAP 5.0.7 software with default 
parameters (https://github.com/iontorrent/TS). Subsequently 
variant calling was done using the Ion Torrent specific caller, 
Torrent Variant Caller (TVC)-5.0.2, using the recommended 
Variant Caller Parameter for Cancer Hotspot Panel v2. Vari-
ant interpretation was done using Geneticist Assistant (Soft-
genetics) which assigns Functional Prediction, Conservation 
scores and Disease associated information to each variant 
(http://softgenetics.com/GeneticistAssistant_2.php). Once 
pathogenicity is assigned to a variant, the same pathogenic-
ity is automatically attributed the next time the variant is 
observed. Integrative Genomics Viewer (IGV) was used 
for visually inspecting variants (doi: 10.1093/bib/bbs017). 
The analysis of the complete APC gene was performed as 
described previously [8]. LOH was analyzed by comparison 
of variant and wild type DNA reads of the NGS results.
Case report
We describe a female patient with a family history of ovarian 
cancer (one sister at the age of 56 years), breast cancer (one 
sister at the age of 59 years), colon cancer (patient’s mother 
at the age of 80 years) and a (non melanoma) skin cancer 
(the sister diagnosed with breast cancer). The index patient 
had one hyperplastic polyp removed from the rectum at the 
age of 43. Aged 44, she was diagnosed with bilateral endo-
metrioid carcinoma of the ovaries with focally mucinous 
differentiation (Fig. 1), clinical stage 1B according to the 
FIGO staging system. Surgery was performed and she was 
treated with adjuvant chemotherapy comprising a regimen 
of cyclofosfamide and carboplatin. At age 45, 12.5 months 
later, she was diagnosed with an adenocarcinoma of the 
colon, treated by a left-sided hemicolectomy. Based on these 
clinical records the patient met the Amsterdam/Bethesda 
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Fig. 1  Shows the histological picture of the ovarian tumor (a, b) and the colon tumor (c, d). In a, b both endometrioid and mucinous parts of the 
ovarian tumor are shown
Table 1  Pathogenic variants, promoter methylation status and immunohistochemical expression of mismatch repair genes in the ovarian tumor, 
colon tumor and leukocyte DNA
The table shows an overview of the detected pathogenic variants, methylation assays and immunohistochemical staining results of mismatch 
repair genes in one of the ovarian tumors, the colon tumor and DNA isolated from blood
LOH loss of heterozygosity, IHC immunohistochemical staining, T% tumor cell percentage
Gene Ovary (T%: > 60%) Colon (T%: > 50%) Lymphocytes
TP53 No pathogenic variant c.1024C > T, p.(Arg342*)/
6,1% mutant reads
MLH1 c.1624C > T, p.(Gln542*)/
76% mutant reads
LOH
Loss of expression by IHC
No promoter hypermethylation
c.1624C > T, p.(Gln542*)/
52% mutant reads
LOH
Loss of expression by IHC
No promoter hypermethylation
No pathogenic variant
CTNNB1 c.134C > T, p.(Ser45Phe)/
9,2% mutant reads
c.134C > T, p.(Ser45Phe)
38% mutant reads
PMS2 Loss of expression by IHC Loss of expression by IHC No pathogenic variant
MSH2 Normal expression by IHC Normal expression by IHC No pathogenic variant
MSH6 Normal expression by IHC Normal expression by IHC No pathogenic variant
APC No pathogenic variant No pathogenic variant
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revised criteria. Patient has remained disease-free until the 
age of 64. However, the discovery of the (mucinous) colon 
carcinoma showing partly a similar morphology as the ovar-
ian tumors (Fig. 1), created doubt about the primary ori-
gin of the ovarian tumors. Lynch syndrome (LS), in which 
independent ovarian and colon tumors had developed, was 
suggested.
Immunohistochemistry testing of the MMR proteins 
MLH1, PMS2, MSH2 and MSH6 of the colonic and ovarian 
tumors showed DNA MMR deficiency with loss of expres-
sion of MLH1 and PMS2. Microsatellite instability (MSI) 
testing using mononucleotide microsatellite markers showed 
an MSI-H phenotype. A sporadic origin of these MMR defi-
cient tumors due to MLH1 promoter hypermethylation was 
excluded. Our patient was subsequently referred to a clinical 
geneticist. However LS could not be confirmed after nega-
tive lymphocyte DNA testing of MLH1, PMS2, MHS2 and 
MSH6 for germline pathogenic variants. Also germline test-
ing of BRCA1 and BRCA2 in two sisters of the patient was 
negative.
Reevaluation of the metachronously diagnosed colon 
tumor confirmed the primary origin in the colon as the bulk 
of the tumor was bulging in the colonic lumen. Furthermore, 
the serosal lining was unaffected. Immunohistochemical 
stainings of the ovarian tumor showed a phenotype compat-
ible with a metastasis from a colon tumor (keratin-7 negative 
/ keratine-20 and CDX-2 positive). ER, PR and vimentin 
were also negative. However, ovarian tumors with muci-
nous differentiation can show a wide variety of keratine-7/
keratin-20 immunoprofile patterns, and should be interpreted 
with caution [9].
Somatic testing (Table 1) of MLH1 showed an iden-
tical MLH1 class 5 pathogenic variant (c.1624C > T, 
p.(Gln542*)) in both colon and ovarian tumors. Next, 
loss of heterozygosity for MLH1 was shown by absence 
of the WT(wild type)-allele. We also somatically tested 
the complete APC gene for pathogenic variants in these 
lesions, as finding of pathogenic APC variants in ovarian 
neoplasms would point at a colonic origin of the lesions. 
No APC variants were found, however an identical acti-
vating class 5 CTNNB1 pathogenic variant (c.134C > T; 
p.(Ser45Phe)) was identified, the molecular alternative 
for Wnt-pathway activation (Fig.  2a). Finding identi-
cal MLH1 and CTNNB1 variants would suggest a clonal 
relation between the colon and ovarian tumor. Addition-
ally, a class 5 pathogenic TP53 variant (c.1024C > T, 
Fig. 2  a Shows the reads 
including the pathogenic 
CTNNB1 variant that is present 
in both the ovarian and the 
colon tumor. b Shows the reads 
including the pathogenic TP53 
variant that is present in the 
colon tumor, but not in the ovar-
ian tumor
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p.(Arg342*)) was detected in the colon tumor, but absent 
in the ovarian tumor (Fig.  2b). In order to estimate 
putative germline mosaicism we performed ultra-deep 
sequencing of the MLH1 (c.1624C > T, p.(Gln542*)) 
variant in DNA isolated from normal colonic mucosa, 
saliva, blood and urine. All isolates showed sufficient 
(> 10 K) coverage, but showing no presence of the MLH1 
variant, rendering germline mosaicism unlikely. It was 
concluded that a metachronously diagnosed colorectal 
tumor that metastasized to both ovaries was the most 
likely diagnosis.
Discussion
In the current report we address a remarkable clinical 
dilemma once metachronous ovarian and colon tumors are 
diagnosed and the possibility of a Lynch syndrome needs to 
be answered. The female patient we now present with bilat-
eral ovarian cancer was treated as having primary bilateral 
ovarian cancer. However, only 12.5 months after the first 
diagnosis the true primary origin of these lesions was ques-
tioned with the resection of a DNA mismatch repair deficient 
left sided colon cancer. After reevaluation and molecular 
analysis a clonal relation was identified between the ovarian 
and colonic lesions. As MMR deficient cancers mostly lack 
distant metastases possibly due to the interaction with the 
immune system, it is noteworthy that this DNA MMR defi-
cient colon cancer probably metastasized to the ovaries [10].
About 15% of all ovarian tumors turn out to be metas-
tases [2]. Histological parameters are not always sufficient 
to discriminate between a primary tumor and/or metasta-
sis. Nowadays, molecular analysis can be a helpful tool to 
make this distinction in selected cases [11]. Inactivating 
APC pathogenic variants are almost exclusively found in 
colon tumors. Thus, the presence of a pathogenic variant is a 
strong argument for a primary colon tumor [3, 11, 12]. In our 
patient no pathogenic variants in the APC gene were found, 
but an identical activating CTNNB1 variant was present in 
both ovary and colon tumors. As CTNNB1 variants are very 
rare in colon carcinomas, this might suggest the ovarian 
tumor as the primary origin [13]. On the other hand activat-
ing CTNNB1 pathogenic variants are often found in colon 
cancer associated with DNA mismatch repair deficiency 
[14–16]. Only an incidental report of metastatic mismatch 
repair deficient colon carcinoma to the ovaries is described 
[17]. In previous published research we did not find any 
CTNNB1 pathogenic variants in MMR proficient colorec-
tal metastases to the ovary [11]. With respect to the ovary, 
CTNNB1 pathogenic variants have mainly been found in 
endometrioid ovarian cancers [13]. However, the histopatho-
logical findings in our case do not suggest metastases from 
the ovary since the colonic tumor was located at the luminal 
site. In case of a metastasis the bulk of the tumor would have 
been present on the serosal site. Besides, ovarian cancers 
metastasizing to the colon, and morphologically mimicking 
a primary colon tumor are probably very rare. Furthermore 
in case of bilateral ovarian tumors the odds favor metastases 
from a primary tumor elsewhere in the body.
In our patient the same somatic MLH1 pathogenic vari-
ant and concomitant loss of heterozygosity of the wild type 
allele was present in the ovarian and colon cancer. As the 
detected MLH1 variant was not found by deep sequencing of 
DNA isolated from normal mucosa, saliva, blood and urine 
a germline mosaicism was rendered unlikely.
Somatic MLH1 pathogenic variants in sporadic tumors 
are mainly associated with gastrointestinal tumors [13, 
18]. MLH1 pathogenic variants are not commonly found in 
ovarian cancer, although one study found MLH1 pathogenic 
variants in 8.7% epithelial ovarian cancer [19]. Usually, 
TP53 pathogenic variants occur early in the evolutionary 
development of a tumor. Our patient’s tumors showed in 
two tumors CTNNB1 as well as MLH1 pathogenic variants, 
but only in the colon tumor a TP53 pathogenic variant was 
identified. The presence of this variant can be explained by 
tumor progression within the primary colon tumor. Appar-
ently in this case, the pathogenic TP53 variant is not pre-
sent in the metastasizing clone. Such spatial differences in 
mutation profiles within a tumor are known as intra-tumor 
heterogeneity.
In summary, we discuss the clinical dilemma with 
metachronous diagnosed bilateral mismatch repair deficient 
ovarian and colon cancer harboring a pathogenic MMR vari-
ant. In our case Lynch syndrome as well as a postzygotic 
somatic mutation leading to mosaicism of multiple normal 
tissues are very unlikely. Molecular analysis showed a clonal 
relationship between the ovarian and colon tumors with his-
topathological analysis suggesting the colon tumor being the 
primary tumor.
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